Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?

被引:0
|
作者
Sedky, Mohamed [1 ,2 ]
Gohar, Seham [1 ]
Ahmed, Sonia [1 ,3 ]
Zaky, Iman [4 ,5 ]
Salama, Asmaa [6 ,7 ]
Hassanein, Omayma [8 ]
Maher, Eslam [8 ]
Elhaddad, Alaa [1 ,3 ]
机构
[1] Children Canc Hosp Egypt 57357 1, Dept Pediat Oncol, Sekket Al Imam St, Cairo 11617, Egypt
[2] Natl Res Ctr, Dept Pediat, Cairo, Egypt
[3] Cairo Univ, Natl Canc Inst, Dept Pediat Oncol, Cairo, Egypt
[4] Children Canc Hosp Egypt 57357, Dept Radiol, Cairo 11617, Egypt
[5] Cairo Univ, Natl Canc Inst, Dept Radiol, Cairo, Egypt
[6] Childrens Canc Hosp 57357, Dept Pathol, Cairo 11617, Egypt
[7] Cairo Univ, Natl Canc Inst, Dept Pathol, Cairo, Egypt
[8] Childrens Canc Hosp 57357, Dept Clin Res, Cairo 11617, Egypt
关键词
Pulmonary; LCH; Multisystem; Survival; RO-; RO plus; Lung lesions; Severity; CHILDREN; DISEASE; INVOLVEMENT; DIAGNOSIS; EVOLUTION; THERAPY;
D O I
10.1186/s13023-023-02970-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background The pediatric pulmonary multisystem Langerhans cell histiocytosis (PPM LCH) is associated with either low risk or high risk organ(s). The nodulo-cystic lung lesions although pathognomonic, yet are very variable in severity and remain a source of controversy in certifying pulmonary LCH diagnosis. The study aimed to examine the prognostic value of clinical respiratory manifestations and radiological lung lesions severity. This is through associating a CT chest triad of bilateral, extensive and diffuse lesions. It is a retrospective study of 350 LCH patients who received systemic treatment at Children's Cancer Hospital Egypt during the period from 2007 to 2020.Results Sixty-seven patients (67/350-19.1%) had PPM LCH at presentation. Severe lung lesions were present in 24 of them. The median follow-up period was 61 months (IQR: 3.4-8.3). The 5-year overall survival (OS) and event free survival (EFS) was 89% and 56.6% respectively. The EFS, for severe radiological lesions triad was 38% +/- 20.7 versus 66% +/- 16.2 for non-severe lesions triad p 0.002, while for presence of chest X-ray changes 27% +/- 22.344 versus absence of chest X ray changes 66% +/- 14.7 p 0.001, for clinical respiratory manifestations 13% +/- 13.9 versus none 62% +/- 22.9 p < 0.001, for RO- with severe lung lesions 47% +/- 30.4 versus RO- without severe lung lesions 69% +/- 5.9 p 0.04. There was a tendency for the independent prognostic impact of severe lung involvement; aHR = 1.7 (95% CI 0.92-3.13, p = 0.09).Conclusion Although the lung is a low -risk organ per se in LCH, our study demonstrates a non negligeable prognostic impact of severe lung involvement in the risk stratification of pediatric LCH. This warrants further study and external validation.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification
    Gadner, Helmut
    Grois, Nicole
    Poetschger, Ulrike
    Minkov, Milen
    Arico, Maurizio
    Braier, Jorge
    Broadbent, Valerie
    Donadieu, Jean
    Henter, Jan-Inge
    McCarter, Robert
    Ladisch, Stephan
    BLOOD, 2008, 111 (05) : 2556 - 2562
  • [22] Patchy Colitis and Interstitial Lung Disease - Multisystem Langerhans Cell Histiocytosis
    Coronel, Emmanuel
    Micic, Dejan
    Rubin, David T.
    GASTROENTEROLOGY, 2015, 148 (01) : 26 - 27
  • [23] OUTCOME OF LIVER INVOLVEMENT IN PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS
    Gohar, Seham
    Sedky, Mohamed
    Ali, Nesreen
    Zaki, Iman
    Salama, Asmaa
    Reda, Hala
    Hassanain, Omayma
    EL Hadad, Alaa
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [24] Multisystem Langerhans cell histiocytosis: A diagnostic chameleon
    Vaidya, Sameer
    Gothi, Dipti
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (07) : 159 - 160
  • [25] Multisystem involvement of Langerhans cell histiocytosis in an adult
    Samanci, Nilay Sengul
    Ayer, Mesut
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2019, 149 (01) : 78 - 79
  • [26] Treatment for multisystem Langerhans' cell histiocytosis - Reply
    Gadner, H
    Ladisch, S
    JOURNAL OF PEDIATRICS, 2002, 140 (02): : 280 - 280
  • [27] Langerhans' cell histiocytosis with multisystem involvement in an adult
    Liu, Y. H.
    Fan, X. H.
    Fang, K.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2007, 32 (06) : 765 - 768
  • [28] MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS IN ADULTS
    MCLELLAND, J
    CHU, AC
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1990, 15 (02) : 79 - 82
  • [29] Cyclosporine A therapy for multisystem Langerhans cell histiocytosis
    Minkov, M
    Grois, N
    Broadbent, V
    Ceci, A
    Jakobson, A
    Ladisch, S
    Gadner, H
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 33 (05): : 482 - 485
  • [30] MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS WITH PANCREATIC INVOLVEMENT
    YU, RCH
    ATTRA, A
    QUINN, CM
    KRAUSZ, T
    CHU, AC
    GUT, 1993, 34 (04) : 570 - 572